MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms

The Medicines Co. and partner Alnylam Pharmaceuticals have presented new evidence supporting the long-term use of their RNA-based cholesterol lowering therapy inclisiran, which is meant to be a longer lasting alternative to a new crop of heart drugs called PCSK9 inhibitors.